ATE475718T1 - Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika - Google Patents

Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika

Info

Publication number
ATE475718T1
ATE475718T1 AT01920143T AT01920143T ATE475718T1 AT E475718 T1 ATE475718 T1 AT E475718T1 AT 01920143 T AT01920143 T AT 01920143T AT 01920143 T AT01920143 T AT 01920143T AT E475718 T1 ATE475718 T1 AT E475718T1
Authority
AT
Austria
Prior art keywords
stearoyl
coa desaturase
therapeutics
identifying
triglyceride reduction
Prior art date
Application number
AT01920143T
Other languages
English (en)
Inventor
Alison Brownlie
Michael Hayden
Alan Attie
James Ntambi
Mark Gray-Keller
Makoto Miyazaki
Original Assignee
Xenon Pharmaceuticals Inc
Wisconsin Alumni Res Found
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc, Wisconsin Alumni Res Found, Univ British Columbia filed Critical Xenon Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE475718T1 publication Critical patent/ATE475718T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
AT01920143T 2000-02-24 2001-02-23 Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika ATE475718T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18452600P 2000-02-24 2000-02-24
US22169700P 2000-07-31 2000-07-31
US25577100P 2000-12-15 2000-12-15
PCT/US2001/005855 WO2001062954A2 (en) 2000-02-24 2001-02-23 Stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents

Publications (1)

Publication Number Publication Date
ATE475718T1 true ATE475718T1 (de) 2010-08-15

Family

ID=27391846

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01920143T ATE475718T1 (de) 2000-02-24 2001-02-23 Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika

Country Status (9)

Country Link
US (5) US6987001B2 (de)
EP (2) EP1315831B8 (de)
JP (2) JP2003533978A (de)
AT (1) ATE475718T1 (de)
AU (4) AU2001247228B2 (de)
CA (1) CA2398940C (de)
DE (2) DE60142692D1 (de)
PT (1) PT1315831E (de)
WO (1) WO2001062954A2 (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6579974B1 (en) * 1998-06-23 2003-06-17 The Regents Of The University Of California Acyl CoA:cholesterol acyltransferase (ACAT-2)
US20030064950A1 (en) * 2001-02-23 2003-04-03 Ntambi James M. Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity
ATE475718T1 (de) * 2000-02-24 2010-08-15 Xenon Pharmaceuticals Inc Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika
CA2430987A1 (en) * 2000-09-26 2002-04-04 Xenon Genetics, Inc. Methods and compositions employing a novel stearoyl-coa desaturase-hscd5
US20020151018A1 (en) * 2000-10-31 2002-10-17 Prouty Stephen M. Stearoyl-CoA desaturase gene promoter
CA2429455A1 (en) * 2000-11-17 2002-05-23 Xenon Genetics Inc. Fat regulated genes, uses thereof, and compounds for modulating same
US20050256068A1 (en) * 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
ATE491474T1 (de) 2001-06-07 2011-01-15 Sang Christine Dr Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor- antagonists
WO2003004692A2 (en) * 2001-07-03 2003-01-16 Xenon Genetics, Inc. Screening processes for agents modulating cholesterol levels
US20050043256A1 (en) * 2001-07-30 2005-02-24 Isis Pharmaceuticals, Inc. Antisense modulation of stearoyl-CoA desaturase expression
JP2005500857A (ja) 2001-08-29 2005-01-13 ゼノン ジェネティクス，インコーポレイテッド 脂肪酸合成酵素を用いたハイスループットスクリーニング分析
US20050119251A1 (en) * 2001-12-21 2005-06-02 Jian-Min Fu Nicotinamide derivatives and their use as therapeutic agents
US7390813B1 (en) 2001-12-21 2008-06-24 Xenon Pharmaceuticals Inc. Pyridylpiperazines and aminonicotinamides and their use as therapeutic agents
AU2003215203A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Short interfering nucleic acid inhibition of stearoyl-coa desaturase (scd) gene
AU2003216482A1 (en) * 2002-03-01 2003-09-16 Exelixis, Inc. MSRAs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2004010927A2 (en) * 2002-07-25 2004-02-05 Wisconsin Alumni Research Foundation Method for increasing insulin sensitivity and for treating and preventing type 2 diabetes
EP1431399A1 (de) * 2002-12-20 2004-06-23 Clinigenetics Verfahren und Zusammen setzung zur Identifizierung von therapeutischen Mitteln gegen atheriosklerotische Plaques
CA2533898A1 (en) * 2003-07-29 2005-02-10 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
WO2005011653A2 (en) 2003-07-30 2005-02-10 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7759348B2 (en) 2003-07-30 2010-07-20 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
US7754711B2 (en) * 2003-07-30 2010-07-13 Xenon Pharmaceuticals Inc. Pyridazine derivatives and their use as therapeutic agents
EP2316825A1 (de) 2003-07-30 2011-05-04 Xenon Pharmaceuticals Inc. Pyridyl Derivate und deren Verwendung als therapeutische Wirkstoffe
US7456180B2 (en) * 2003-07-30 2008-11-25 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
RU2326118C2 (ru) * 2003-07-30 2008-06-10 Зинон Фармасьютиклз Инк. Производные пиридазина и их применение в качестве терапевтических агентов
HRP20110974T1 (hr) 2003-07-30 2012-01-31 Xenon Pharmaceuticals Inc. Derivati piperazina i njihova uporaba kao terapeutskih sredstava
US7285395B2 (en) * 2004-06-09 2007-10-23 Wisconsin Alumni Research Foundation Stearoyl-CoA desaturase 4 gene
ATE537830T1 (de) * 2004-07-06 2012-01-15 Xenon Pharmaceuticals Inc Nicotinamid derivate und ihre verwendung als therapeutika
TW200626153A (en) 2004-09-20 2006-08-01 Xenon Pharmaceuticals Inc Heterocyclic derivatives and their use as therapeutic agents
MX2007003321A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
CN101084207A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
EP1804799B1 (de) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterozyklische Derivate und ihre Verwendung als Stearoyl-Coa-Desaturase-Inhibitoren
EP1807085B1 (de) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterozyklische Derivate und ihre Verwendung als Stearoyl-Coa-Desaturase-Inhibitoren
AR051094A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
CN101083982A (zh) 2004-09-20 2007-12-05 泽农医药公司 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物
WO2006034312A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd)
WO2007046868A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Thiazolidine derivatives and their uses as therapeutic agents
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
US20060281071A1 (en) * 2005-06-08 2006-12-14 Ntambi James M Stearoyl-CoA desaturase assay
US20070231335A1 (en) * 2005-07-20 2007-10-04 Bruce Beutler Compositions and methods for treating Gram positive bacterial infection in a mammalian subject
MX2008015229A (es) 2006-06-05 2008-12-12 Novartis Ag Compuestos organicos.
US8063084B2 (en) 2006-08-15 2011-11-22 Novartis Ag Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
WO2008024390A2 (en) 2006-08-24 2008-02-28 Novartis Ag 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders
US20080182249A1 (en) * 2006-09-01 2008-07-31 Fox Brian G Expression systems for mammalian and mycobacterial desaturases
EP1932921A1 (de) * 2006-12-13 2008-06-18 Novartis AG Einfaches, auf Mutanten basierendes, differentielles Screening-Verfahren für ein spezifisches Ziel modulierende Zusammensetzungen
US8153392B2 (en) * 2007-05-10 2012-04-10 Undurti N Das Method(s) of preventing, arresting, reversing and treatment of atherosclerosis
WO2008157844A1 (en) * 2007-06-21 2008-12-24 Forest Laboratories Holdings Limited Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase
JP5465177B2 (ja) 2007-09-20 2014-04-09 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇｐｒ１１９活性のモジュレーターとしての化合物および組成物
GB0722077D0 (en) 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
JP2011525478A (ja) 2008-03-20 2011-09-22 フォレスト・ラボラトリーズ・ホールディングス・リミテッド ステアロイル−ＣｏＡデサチュラーゼの阻害剤としての新規ピペラジン誘導体
CN102036558A (zh) 2008-03-20 2011-04-27 森林实验室控股有限公司 作为硬脂酰-CoA去饱和酶抑制剂的新颖哌啶衍生物
EP2307379A2 (de) 2008-06-27 2011-04-13 Novartis AG Organische verbindungen
EP2161580A1 (de) * 2008-09-02 2010-03-10 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Biomarker zur Identifizierung von prädispositionierten Patienten zur Entwicklung einer Insulinresistenz und Bestimmung des Insulinresistenzstatus
US20110184027A1 (en) * 2008-09-25 2011-07-28 Glenmark Pharmaceuticals S.A. Tissue selective stearoyl-coa desaturase 1 inhibitors and cell based screening assay for their identification
US20100160323A1 (en) * 2008-12-23 2010-06-24 Alexander Bischoff NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE
EP2414366A1 (de) 2009-04-01 2012-02-08 Novartis AG Spiro-derivate zur modulation von stearoyl-coa-desaturase
WO2011030312A1 (en) 2009-09-10 2011-03-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) NOVEL INHIBITORS OF STEAROYL-CoA-DESATURASE-1 AND THEIR USES
CN102574841A (zh) 2009-10-01 2012-07-11 诺瓦提斯公司 调节硬脂酰-coa去饱和酶的吡唑衍生物
WO2011163560A1 (en) * 2010-06-25 2011-12-29 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Methods of treatment using sterculic acid
KR20140084164A (ko) * 2011-10-15 2014-07-04 제넨테크, 인크. 암의 치료를 위한 scd1 길항제
DE102014005771A1 (de) 2014-04-23 2015-10-29 Clariant International Ltd. Verwendung von wässrigen driftreduzierenden Zusammensetzungen
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
MA47212A (fr) 2017-01-06 2019-11-13 Yumanity Therapeutics Inc Méthodes de traitement de troubles neurologiques
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
CN112312913B (zh) 2018-03-23 2024-03-08 詹森药业有限公司 化合物和其用途
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
WO2023023227A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
WO2023023220A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3274330D1 (en) * 1982-08-02 1987-01-08 Unitika Ltd An intravenous nutrient
NZ219230A (en) 1986-02-14 1991-06-25 Medeva Plc Method of modifying cell membranes by using c12 - c28 saturated fatty acids
JP3070611B2 (ja) * 1989-03-07 2000-07-31 サントリー株式会社 △▲上５▼―不飽和化酵素阻害剤
US5162179A (en) 1990-04-17 1992-11-10 Armstrong World Industries, Inc. Electrographic structure and process
WO1991018985A1 (en) * 1990-05-25 1991-12-12 E.I. Du Pont De Nemours And Company Nucleotide sequence of soybean stearoyl-acp desaturase gene
US5336974A (en) * 1991-12-23 1994-08-09 U.S. Philips Corporation High-pressure discharge lamp
US5554646A (en) 1992-04-29 1996-09-10 Wisconsin Alumni Research Foundation Method for reducing body fat in animals
US5861485A (en) 1994-08-23 1999-01-19 Millennium Pharmaceuticals, Inc. Polypeptides involved in body weight disorders, including obesity
US6162455A (en) * 1997-01-22 2000-12-19 American Cyanamid Company Method for increasing lean meat, improving the lean meat to fat ratio and improving amino acid utilization in warm-blooded animals
CA2307941C (en) 1997-06-23 2008-09-09 Cornell Research Foundation, Inc. Method of altering nutritional components of milk produced by a lactating animal
AU4414999A (en) 1998-06-08 1999-12-30 Sambasiva R. Chavali Inhibition of delta-9-desaturase activity by saponins
AU5774699A (en) 1998-08-14 2000-03-06 Johnson & Johnson Consumer Companies, Inc. Human stearoyl-coa desaturase-related compositions and methods for treating skin disorders
US20030064950A1 (en) * 2001-02-23 2003-04-03 Ntambi James M. Methods for reducing body fat and increasing lean body mass by reducing stearoyl-CoA desaturase 1 activity
ATE475718T1 (de) 2000-02-24 2010-08-15 Xenon Pharmaceuticals Inc Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika
CA2632936A1 (en) * 2005-12-20 2007-06-28 Merck Frosst Canada Ltd. Heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
TW200826936A (en) * 2006-12-01 2008-07-01 Merck Frosst Canada Ltd Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase

Also Published As

Publication number Publication date
AU2007201711A1 (en) 2007-05-10
US20110060014A1 (en) 2011-03-10
US7790408B1 (en) 2010-09-07
EP1315831A2 (de) 2003-06-04
WO2001062954A3 (en) 2003-03-27
US7696151B2 (en) 2010-04-13
DE60142692D1 (de) 2010-09-09
DE01920143T9 (de) 2005-04-28
DE01920143T1 (de) 2004-05-19
EP2172560A2 (de) 2010-04-07
JP2003533978A (ja) 2003-11-18
US20030157552A1 (en) 2003-08-21
JP2008131939A (ja) 2008-06-12
AU2010200879B2 (en) 2012-01-19
US7816075B2 (en) 2010-10-19
CA2398940A1 (en) 2001-08-30
CA2398940C (en) 2012-02-21
EP1315831B8 (de) 2010-09-01
WO2001062954A8 (en) 2002-02-14
AU2007201711B2 (en) 2009-12-10
US20050250160A1 (en) 2005-11-10
EP2172560A3 (de) 2010-09-29
US20050256033A1 (en) 2005-11-17
EP1315831B1 (de) 2010-07-28
US6987001B2 (en) 2006-01-17
AU4722801A (en) 2001-09-03
WO2001062954A2 (en) 2001-08-30
AU2001247228B2 (en) 2007-01-18
AU2010200879A1 (en) 2010-04-01
PT1315831E (pt) 2010-11-04

Similar Documents

Publication Publication Date Title
ATE475718T1 (de) Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika
ATE195527T1 (de) Neue steroidester zur behandlung von hauterkrankungen
DK0606012T3 (da) Sammensætninger indeholdende cholesterylestere af umættede fedtsyrer
EP1366012A4 (de) 2-aryloxy-2-arylalkansäuren gegen diabetes und störungen des fettstoffwechsels
ATE430193T1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
ATE344027T1 (de) Fettsäurederivat zur behandlung von externen sekretionsstörungen
EP1360965A4 (de) Verfahren zur behandlung von krankheiten in zusammenhang mit einer abnahme der expression des aop-1-gens oder aop-1 und mittel zur behandlung der krankheiten
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
ATE356113T1 (de) Probucolbernsteinsäureester zur hemmung der expression von vcam-1
TW429145B (en) Pharmaceutical composition for treating schizophrenia, tardive dyskinesia, depression, and alzheimer's disease comprising EPA/SA
ATE202940T1 (de) Mittel und methoden zur behandlung von plaque- krankheiten
BR9905398A (pt) Derivados de fitoesteróis e/ou fitoestanóis
EP1381276A4 (de) Verfahren zur behandlung oder zur entwicklungsverlangsamung von blindheit
DE69620306D1 (de) 4-(.Alpha.-hydroxy-.alpha.-aryl-alkylcarbonylamino)-Piperidine zur Behandlung und Prophylaxe von Erkrankungen der Harnwege
DE19781988T1 (de) Verfahren zur Herstellung von Methacrylsäureestern oder Acrylsäureestern
ATE135208T1 (de) Verwendung von nervonsäure und langkettiger fettsäuren zur behandlung demyelinisierender erkrankungen
EP1411916A4 (de) Verfahren und materialien für die behandlung des testosteron-mangels bei männern
ATE374618T1 (de) Verwendung von rekombinanten menschlichen uteroglobin zur behandlung von fibrotischen krankheitszuständen
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
EP1058546A4 (de) Zusammenstellungen und methoden zur behandlung von erkrankungen der macula
DE69636510D1 (de) Verwendung von phosphoglyzeriden enthaltend phosphoglycero-ether zur behandlung neurodegenerativer erkrankungen in geistig schwer behinderten kindern
EE03953B1 (et) 2-fenüül-1,2-bensisoseleenasool-3(2H)-ooni kasutamine farmatseutilise preparaadi valmistamisel Alzheimeri tõve raviks
ATE269705T1 (de) Verwendung von optisch reinem (r)-tofizopam zur behandlung und pravention von angststörungen
DE59900222D1 (de) Verwendung von hyperforin und hyperforinhaltigen extrakten zur behandlung und prophylaxe von demenzerkrankungen
DE60329588D1 (de) Verwendung von epa and dha zur sekundären prevention von schlaganfällen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1315831

Country of ref document: EP